You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
盘中异动 | 药明生物盘中大涨8%,报于67.45港元
uSMART盈立智投 02-09 09:32

2022年2月9日9时32分,药明生物(HK02269)盘中大涨8%,报于67.45港元,成交额达11.96亿港元,换手率达到0.01%。

2月9日讯,药明生物(02269)发布公告,该公司股份将于2022年2月9日上午9时正起恢复买卖。同时,与该公司有关的所有结构性产品亦将恢复买卖。

2月8日,安信证券:国内CXO受“UVL清单”影响较小,行业景气度持续。2月8日,国盛证券:维持药明生物(02269)“买入”评级,业绩持续高增长。2月8日,中泰证券:维持药明生物(02269)“买入”评级,2021年度业绩预告超预期。

最新的财务数据显示,公司于2021年2季度,营业收入44.07亿人民币,净利润18.83亿人民币;营业收入同比增加126.67%,毛利润同比增加190.8%,净利润同比增加157.67%。

盈立趋势长盈模型最近一次交易信号,2022年2月8日出现观望信号,触发价格为62.25港元(信号仅供参考)。

uSMART智能写手的信息、数据均来自媒体公开报道,智能写手不能保证其完全准确,内容仅供参考,不构成投资建议。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account